This review article, titled "Mortality prevention as the center of COPD management," by Andriana I Papaioannou, Georgios Hillas, Stelios Loukides, and Theodoros Vassilakopoulos, focuses on the importance of mortality prevention in the management of Chronic Obstructive Pulmonary Disease (COPD). The authors highlight that COPD is a significant healthcare issue and a leading cause of mortality worldwide, with patients at increased risk of death based on symptom severity, lung function, exercise capacity, and comorbidities such as cardiovascular diseases and metabolic disorders. The article discusses various non-pharmacological and pharmacological interventions aimed at reducing mortality in COPD patients, including smoking cessation, long-term oxygen therapy, non-invasive mechanical ventilation, lung volume reduction surgery, pulmonary rehabilitation, and pharmacological treatments like triple therapy (ICS/LABA/LAMA combinations). Recent studies have shown encouraging results for triple therapy, which has been found to reduce mortality compared to dual therapies. The authors review the data from major trials such as TORCH, UPLIFT, SUMMIT, IMPACT, and ETHOS, which have evaluated the efficacy of these treatments. While some trials did not show statistically significant reductions in mortality, others, like ETHOS, demonstrated a 49% reduction in the risk of death from any cause. The article emphasizes the importance of identifying patients who would benefit most from triple therapy, particularly those with high blood eosinophil levels. The discussion section highlights the challenges in studying COPD mortality due to the complex interplay between the disease and comorbidities, as well as the impact of various factors such as exacerbation frequency and severity. The authors conclude that while recent studies on triple therapy show promising results, more research is needed to fully understand the mechanisms and optimal use of these treatments.This review article, titled "Mortality prevention as the center of COPD management," by Andriana I Papaioannou, Georgios Hillas, Stelios Loukides, and Theodoros Vassilakopoulos, focuses on the importance of mortality prevention in the management of Chronic Obstructive Pulmonary Disease (COPD). The authors highlight that COPD is a significant healthcare issue and a leading cause of mortality worldwide, with patients at increased risk of death based on symptom severity, lung function, exercise capacity, and comorbidities such as cardiovascular diseases and metabolic disorders. The article discusses various non-pharmacological and pharmacological interventions aimed at reducing mortality in COPD patients, including smoking cessation, long-term oxygen therapy, non-invasive mechanical ventilation, lung volume reduction surgery, pulmonary rehabilitation, and pharmacological treatments like triple therapy (ICS/LABA/LAMA combinations). Recent studies have shown encouraging results for triple therapy, which has been found to reduce mortality compared to dual therapies. The authors review the data from major trials such as TORCH, UPLIFT, SUMMIT, IMPACT, and ETHOS, which have evaluated the efficacy of these treatments. While some trials did not show statistically significant reductions in mortality, others, like ETHOS, demonstrated a 49% reduction in the risk of death from any cause. The article emphasizes the importance of identifying patients who would benefit most from triple therapy, particularly those with high blood eosinophil levels. The discussion section highlights the challenges in studying COPD mortality due to the complex interplay between the disease and comorbidities, as well as the impact of various factors such as exacerbation frequency and severity. The authors conclude that while recent studies on triple therapy show promising results, more research is needed to fully understand the mechanisms and optimal use of these treatments.